Related Experiment Video

Updated: Dec 20, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.2K

Actovegin® reduces PMA-induced inflammation on human cells

Franz-Xaver Reichl1, Christof Högg2, Fangfang Liu2

  • 1Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich, Goethestr. 70, 80336, Munich, Germany. reichl@lmu.de.

European Journal of Applied Physiology
|May 25, 2020
PubMed
Abstract

Insights

Actovegin® reduces inflammation by decreasing interleukin-1 beta release and reactive oxygen species production in human peripheral blood mononuclear cells (PBMCs) stimulated with phorbol 12-myristate 13-acetate (PMA). This may explain its clinical benefits for inflammatory athletic injuries.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Peripheral blood mononuclear cells (PBMCs) play a crucial role in inflammatory responses.
  • Phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS) are common stimuli used to induce inflammation in vitro.
  • Actovegin® is a drug with potential anti-inflammatory properties.

Purpose of the Study:

  • To investigate the effect of Actovegin® on PMA- and LPS-induced human PBMCs.
  • To assess Actovegin®'s impact on cytokine secretion and reactive oxygen species (ROS) production.

Main Methods:

  • Human PBMCs were exposed to Actovegin® with or without PMA or LPS.
  • Cytokine concentrations (TNF-α, IL-1beta, IL-6, IL-10) in supernatants were measured.
  • Reactive oxygen species (ROS) production was assessed using a ROS-Glo™ assay.

Main Results:

  • PMA and LPS significantly increased cytokine secretion from PBMCs.
  • Actovegin® pre-treatment significantly decreased IL-1beta secretion induced by PMA.
  • Actovegin® did not alter IL-1beta production induced by LPS.
  • Actovegin® did not affect TNF-α, IL-6, or IL-10 secretion in the context of PMA or LPS stimulation.

Conclusions:

  • Actovegin® demonstrates an ability to reduce PMA-induced IL-1beta release and ROS production in PBMCs.
  • These findings support the potential therapeutic role of Actovegin® in managing inflammatory conditions, such as athletic injuries.
Keywords:
Human PBMCsIL1-betaLPSPMAROSSports

More Related Videos

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.8K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.1K

Related Concept Videos

Inflammation01:38

Inflammation

Overview
61.1K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
370
Inflammatory Response II: Inflammatory Exudate and Tissue Repair01:24

Inflammatory Response II: Inflammatory Exudate and Tissue Repair

The immune system's inflammatory response destroys the invading pathogen, permitting the tissue to heal. The changes during the cellular and vascular stages allow exudate formation at the site of inflammation. The inflammatory exudate released from the wound has high protein content and a specific gravity above 1.020.
The typical wound exudate is odorless, transparent, straw-colored, thin, and watery. Exudate, however, can differ depending on the state of wound healing. Likewise, the...
6.9K
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
15.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.2K